RNA interference (RNAi) provides an attractive tool to modulate biological systems, and ultimately, to treat human diseases. We describe early results from a Phase Ib, first-in-human safety and tolerability study of an RNAi-based therapy, NUC B1000, among patients with mild to moderate chronic HBV.
Methods
Three subjects received a single 5 mg DNA dose of NUC B1000 as part of a planned dose escalation study.
Results
All participants reported pharyngitis, chills, myalgia and fever approximately 4–7 h after dosing. All subjects were asymptomatic after a single antipyretic dose with no symptom recurrences. Measurements of interferon (IFN)-α and -γ, interleukin (IL)-10, 12 18, 8 and 6, and tumour necrosis factor-α performed before and after dosing revealed cytokine increases before study drug administration. After drug administration, IFN-γ and IL-10 increased in two patients; IL-8 increased in one. Most increases returned to pretreatment levels within 1 week. Two patients were subsequently successfully treated with entecavir indicating that NUC B1000 does not compromise subsequent antiviral therapy.
Conclusions
Thus far, NUC B1000 appears safe and well-tolerated; safety and efficacy studies across a larger, more diverse patient spectrum using increasing doses are needed to determine its appropriate role in the antiviral armamentarium.
References
1.
HajeriP.B., SinghS.K.siRNAs: their potential as therapeutic agents – Part I. Designing of siRNAs. Drug Discov Today2009; 14: 851–858.
2.
SinghS.K., HajeriP.B.siRNAs: their potential as therapeutic agents – Part II. Methods of delivery. Drug Discov Today2009; 14: 859–865.
3.
StevensonM.Therapeutic potential of RNA interference. N Engl J Med2004; 351: 1772–1777.
4.
LeeR.C., FeinbaumR.L., AmbrosV.The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell1993; 75: 843–854.
5.
FireA., XuS., MontgomeryM.K.Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature1998; 391: 806–811.
6.
GrimmD., StreetzK.L., JoplingC.L.Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature2006; 441: 537–541.
7.
GuoS., KemphuesK.J.Molecular genetics of asymmetric cleavage in the early Caenorhabditis elegans embryo. Curr Opin Genet Dev1996; 6: 408–415.
8.
NapoliC., LemieuxC., JorgensenR.Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell1990; 2: 279–289.
SioudM.Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol2005; 348: 1079–1090.
15.
ChangJ.J., ThompsonA.J., VisvanathanK.The phenotype of hepatitis B virus-specific T cells differ in the liver and blood in chronic hepatitis B virus infection. Hepatology2007; 46: 1332–1340.
16.
KanzlerH., BarratF.J., HesselE.M., CoffmanR.L.Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med2007; 13: 552–559.
17.
RobbinsM.A., LiM., LeungI.Stable expression of shRNAs in human CD34+ progenitor cells can avoid induction of interferon responses to siRNAs in vitro. Nat Biotechnol2006; 24: 566–571.
